{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:53:38Z","timestamp":1792450418913,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This article has a companion Counterpoint by Cortes.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018018614","type":"journal-article","created":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T16:55:11Z","timestamp":1545843311000},"page":"3648-3652","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Imatinib is still recommended for frontline therapy for CML"],"prefix":"10.1182","volume":"2","author":[{"given":"Andrew","family":"Hantel","sequence":"first","affiliation":[{"name":"Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,12,26]]},"reference":[{"issue":"9","key":"2020021109101249200_B1","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2020021109101249200_B2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2020021109101249200_B3","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2015-06-641043","article-title":"Is there a best TKI for chronic phase CML?","volume":"126","author":"Larson","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2020021109101249200_B4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021109101249200_B5","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2020021109101249200_B6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"2020021109101249200_B7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2020021109101249200_B8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2020021109101249200_B9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1179\/1607845412Y.0000000071","article-title":"EUTOS CML prognostic scoring system predicts ELN-based \u2018event-free survival\u2019 better than Euro\/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate","volume":"18","author":"Uz","year":"2013","journal-title":"Hematology"},{"key":"2020021109101249200_B10","article-title":"Validation of the EUTOS long-term survival score in a recent independent cohort of \u201creal world\u201d CML patients [published online ahead of print 19 April 2018]","author":"Geelen","journal-title":"Leukemia"},{"issue":"24","key":"2020021109101249200_B11","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2020021109101249200_B12","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"20","key":"2020021109101249200_B13","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021109101249200_B14","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"18","key":"2020021109101249200_B15","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood-2012-04-423418","article-title":"Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"121","author":"Hochhaus","year":"2013","journal-title":"Blood"},{"issue":"18","key":"2020021109101249200_B16","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2020021109101249200_B17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"issue":"28","key":"2020021109101249200_B18","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021109101249200_B19","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clml.2016.03.003","article-title":"Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups: A systematic review and meta-analysis of eight randomized trials","volume":"16","author":"Yun","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2020021109101249200_B20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","article-title":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis","volume":"77","author":"Campiotti","year":"2017","journal-title":"Eur J Cancer"},{"key":"2020021109101249200_B21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2020021109101249200_B22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020021109101249200_B23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2020021109101249200_B24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: A systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"2020021109101249200_B25","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hon.2274","article-title":"Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a \u2018real-life\u2019 patient population with chronic myeloid leukaemia","volume":"35","author":"Latagliata","year":"2017","journal-title":"Hematol Oncol"},{"issue":"12","key":"2020021109101249200_B26","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1007\/s00432-017-2517-0","article-title":"Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia","volume":"143","author":"Jiang","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"36","key":"2020021109101249200_B27","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2016.67.4184","article-title":"Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia","volume":"34","author":"Winn","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020021109101249200_B28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020021109101249200_B29","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2020021109101249200_B30","author":"Lexicomp Drug Prices"},{"issue":"1","key":"2020021109101249200_B31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40261-017-0587-z","article-title":"Cost effectiveness of imatinib, dasatinib, and nilotinib as first-line treatment for chronic-phase chronic myeloid leukemia in China","volume":"38","author":"Li","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"7","key":"2020021109101249200_B32","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw003","article-title":"Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States","volume":"108","author":"Padula","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"2020021109101249200_B33","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00277-015-2319-x","article-title":"Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU","volume":"94","author":"Conti","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"2020021109101249200_B34","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1586\/17512433.2013.843450","article-title":"Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies","volume":"6","author":"Kaltenboeck","year":"2013","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/24\/3648\/1554982\/advances018614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/24\/3648\/1554982\/advances018614.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:46:09Z","timestamp":1581414369000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/24\/3648\/15980\/Imatinib-is-still-recommended-for-frontline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,26]]},"references-count":34,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018,12,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018018614","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,26]]}}}